Cargando…
Alterations of redox and iron metabolism accompany the development of HIV latency
HIV‐1 persists in a latent form during antiretroviral therapy, mainly in CD4(+) T cells, thus hampering efforts for a cure. HIV‐1 infection is accompanied by metabolic alterations, such as oxidative stress, but the effect of cellular antioxidant responses on viral replication and latency is unknown....
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196916/ https://www.ncbi.nlm.nih.gov/pubmed/32157726 http://dx.doi.org/10.15252/embj.2019102209 |
_version_ | 1783528787581861888 |
---|---|
author | Shytaj, Iart Luca Lucic, Bojana Forcato, Mattia Penzo, Carlotta Billingsley, James Laketa, Vibor Bosinger, Steven Stanic, Mia Gregoretti, Francesco Antonelli, Laura Oliva, Gennaro Frese, Christian K Trifunovic, Aleksandra Galy, Bruno Eibl, Clarissa Silvestri, Guido Bicciato, Silvio Savarino, Andrea Lusic, Marina |
author_facet | Shytaj, Iart Luca Lucic, Bojana Forcato, Mattia Penzo, Carlotta Billingsley, James Laketa, Vibor Bosinger, Steven Stanic, Mia Gregoretti, Francesco Antonelli, Laura Oliva, Gennaro Frese, Christian K Trifunovic, Aleksandra Galy, Bruno Eibl, Clarissa Silvestri, Guido Bicciato, Silvio Savarino, Andrea Lusic, Marina |
author_sort | Shytaj, Iart Luca |
collection | PubMed |
description | HIV‐1 persists in a latent form during antiretroviral therapy, mainly in CD4(+) T cells, thus hampering efforts for a cure. HIV‐1 infection is accompanied by metabolic alterations, such as oxidative stress, but the effect of cellular antioxidant responses on viral replication and latency is unknown. Here, we show that cells survive retroviral replication, both in vitro and in vivo in SIVmac‐infected macaques, by upregulating antioxidant pathways and the intertwined iron import pathway. These changes are associated with remodeling of promyelocytic leukemia protein nuclear bodies (PML NBs), an important constituent of nuclear architecture and a marker of HIV‐1 latency. We found that PML NBs are hyper‐SUMOylated and that PML protein is degraded via the ubiquitin–proteasome pathway in productively infected cells, before latency establishment and after reactivation. Conversely, normal numbers of PML NBs were restored upon transition to latency or by decreasing oxidative stress or iron content. Our results highlight antioxidant and iron import pathways as determinants of HIV‐1 latency and support their pharmacologic inhibition as tools to regulate PML stability and impair latency establishment. |
format | Online Article Text |
id | pubmed-7196916 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-71969162020-05-04 Alterations of redox and iron metabolism accompany the development of HIV latency Shytaj, Iart Luca Lucic, Bojana Forcato, Mattia Penzo, Carlotta Billingsley, James Laketa, Vibor Bosinger, Steven Stanic, Mia Gregoretti, Francesco Antonelli, Laura Oliva, Gennaro Frese, Christian K Trifunovic, Aleksandra Galy, Bruno Eibl, Clarissa Silvestri, Guido Bicciato, Silvio Savarino, Andrea Lusic, Marina EMBO J Articles HIV‐1 persists in a latent form during antiretroviral therapy, mainly in CD4(+) T cells, thus hampering efforts for a cure. HIV‐1 infection is accompanied by metabolic alterations, such as oxidative stress, but the effect of cellular antioxidant responses on viral replication and latency is unknown. Here, we show that cells survive retroviral replication, both in vitro and in vivo in SIVmac‐infected macaques, by upregulating antioxidant pathways and the intertwined iron import pathway. These changes are associated with remodeling of promyelocytic leukemia protein nuclear bodies (PML NBs), an important constituent of nuclear architecture and a marker of HIV‐1 latency. We found that PML NBs are hyper‐SUMOylated and that PML protein is degraded via the ubiquitin–proteasome pathway in productively infected cells, before latency establishment and after reactivation. Conversely, normal numbers of PML NBs were restored upon transition to latency or by decreasing oxidative stress or iron content. Our results highlight antioxidant and iron import pathways as determinants of HIV‐1 latency and support their pharmacologic inhibition as tools to regulate PML stability and impair latency establishment. John Wiley and Sons Inc. 2020-03-11 2020-05-04 /pmc/articles/PMC7196916/ /pubmed/32157726 http://dx.doi.org/10.15252/embj.2019102209 Text en © 2020 The Authors. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Shytaj, Iart Luca Lucic, Bojana Forcato, Mattia Penzo, Carlotta Billingsley, James Laketa, Vibor Bosinger, Steven Stanic, Mia Gregoretti, Francesco Antonelli, Laura Oliva, Gennaro Frese, Christian K Trifunovic, Aleksandra Galy, Bruno Eibl, Clarissa Silvestri, Guido Bicciato, Silvio Savarino, Andrea Lusic, Marina Alterations of redox and iron metabolism accompany the development of HIV latency |
title | Alterations of redox and iron metabolism accompany the development of HIV latency |
title_full | Alterations of redox and iron metabolism accompany the development of HIV latency |
title_fullStr | Alterations of redox and iron metabolism accompany the development of HIV latency |
title_full_unstemmed | Alterations of redox and iron metabolism accompany the development of HIV latency |
title_short | Alterations of redox and iron metabolism accompany the development of HIV latency |
title_sort | alterations of redox and iron metabolism accompany the development of hiv latency |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196916/ https://www.ncbi.nlm.nih.gov/pubmed/32157726 http://dx.doi.org/10.15252/embj.2019102209 |
work_keys_str_mv | AT shytajiartluca alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT lucicbojana alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT forcatomattia alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT penzocarlotta alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT billingsleyjames alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT laketavibor alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT bosingersteven alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT stanicmia alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT gregorettifrancesco alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT antonellilaura alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT olivagennaro alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT fresechristiank alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT trifunovicaleksandra alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT galybruno alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT eiblclarissa alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT silvestriguido alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT bicciatosilvio alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT savarinoandrea alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency AT lusicmarina alterationsofredoxandironmetabolismaccompanythedevelopmentofhivlatency |